Jyong Biotech (MENS) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NovaBridge Biosciences (NBP) has outperformed Jyong Biotech (MENS) over the past year, losing 73.0% versus a loss of 95.9%. NovaBridge Biosciences is the larger company by market cap ($162.4 million vs $158.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | NBP |
|---|---|---|
| Share price | $2.09 | $1.40 |
| Market cap | $158.90M | $162.40M |
| 1-day change | -0.48% | +2.18% |
| YTD return | -46.84% | -65.58% |
| 1-year return | -95.89% | -72.98% |
| 5-year return | — | -97.92% |
| EPS (TTM) | $-0.06 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $6.79 |
| 52-week low | $1.43 | $1.31 |
| Distance from 52-week high | -96.68% | -79.38% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +542.86% |
| Average volume | 45.62K | 382.99K |
| Shares outstanding | 74.23M | 116.00M |
| Employees | 27 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBP has outperformed MENS by 22.9 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
MENS vs NBP FAQ
Which is bigger, Jyong Biotech or NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $162.40M compared with $158.90M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or NBP?
NBP returned -72.98% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.